Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rhinitis, Allergic, Nonseasonal Clear all
Completed Phase 3 Interventional

An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

NCT00132925
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Triamcinolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 5 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

NCT01133626
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Placebo Nasal Aerosol, Prednisone capsules, Placebo Prednisone Capsules, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
North Dartmouth, Massachusetts • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

NCT00789555
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Olopatadine hydrochloride 0.6% nasal spray (PATANASE), Olopatadine nasal spray vehicle, pH 3.7, Olopatadine nasal spray vehicle, pH 7.0
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

NCT01451541
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
848 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Costa Mesa, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Jul 22, 2026, 8:17 PM EDT
Completed No phase listed Observational

Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

NCT01632540
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
Beclomethasone Dipropionate (BDP) Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
46
States / cities
Little Rock, Alaska • Phoenix, Arizona • Encinitas, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)

NCT00261287
View directory record Official record
Conditions
Hay Fever, Perennial Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Long Beach, California • Normal, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)

NCT00163514
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
58
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study in Adults Sensitized to Cat

NCT00689299
View directory record Official record
Conditions
Allergy
Interventions
Standardized Allergenic Extract, Cat Hair, Placebo
Biological
Lead sponsor
Antigen Laboratories, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Marietta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

NCT00163501
View directory record Official record
Conditions
Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions
Ciclesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
41
States / cities
Encinitas, California • Huntington Beach, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

NasoNeb Delivery of an Intranasal Steroid

NCT01270256
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

NCT00103454
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Mission Viejo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

NCT00449072
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Placebo, TAA-AQ, Nasacort® AQ, Claritin®
Other · Drug
Lead sponsor
Sanofi
Industry
Eligibility
3 Years to 9 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

NCT00116883
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X aqueous nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older

NCT01067105
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide HFA 160 μg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
44
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

A Novel Biologic Therapy for Perennial Allergic Rhinitis

NCT03360071
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Allergen Immunotherapy Extract, Allergen Immunotherapy Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jul 22, 2026, 8:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Efficacy & Safety of the UAS Immunotherapy Protocol

NCT01699659
View directory record Official record
Conditions
Perennial Allergic Rhinitis With Seasonal Variation
Interventions
allergen immunotherapy
Other
Lead sponsor
United Allergy Services
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarkers of Cockroach Sublingual Immunotherapy 2

NCT01380327
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
Cockroach Sublingual Immunotherapy (SLIT) - Low Dose, Placebo, Cockroach Sublingual Immunotherapy (SLIT) - High Dose
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

NCT01287364
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

NCT00570492
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Fluticasone furoate nasal spray, Placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 8 Years
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Oxford, Alabama • Little Rock, Arkansas • Huntington Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

NCT00720382
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, Mometasone furoate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
59
States / cities
Oxford, Alabama • Fountain Valley, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

NCT02709538
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

NCT01697956
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
BDP, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Long Beach, California • Stockbridge, Georgia • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00682643
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
fluticasone furoate nasal spray, vehicle placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
56
States / cities
Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 22, 2026, 8:17 PM EDT